ROBO Global Healthcare Technology and Innovation ETF

HTEC

Market cap $52.1M

The 2026 Brown Brothers Harriman (BBH) Global ETF Investor Survey revealed a constant data point — demand for ETFs remains robust on a global scale. However, the current market environment is shifting the tide, giving way to specific trends in an ETF marketplace that continues to evolve.

TMX VettaFi writers Ben Hernandez and DJ Shaw delved into the world of crypto ETFs in the last Bull vs. Bear. In this edition, writers Nick Peters-Golden and Elle Fitzgerald focus on artificial intelligence — specifically, AI ETFs.

The artificial intelligence and robotics investment opportunity extends far beyond the headline-grabbing tech giants, offering exposure to a diverse ecosystem of enablers and application developers that many investors overlook, according to experts at VettaFi's Winter Symposium on Thursday.

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Healthcare technology continues to offer a powerful combination of health care investing durability and tech innovation upside. In an uncertain market, the segment can often prove a reliable source of performance for portfolios.

Healthcare has been the worst-performing sector in the S&P 500 this year. But when it comes to unlocking potential capital growth ahead, that may not be all bad news.

The future of healthcare is being forged at the intersection of biology and technology. Much like software and data analytics reshaped industries like finance and retail, a similar transformation is now creating a new landscape for investors in medicine.

On this week's episode of ETF Prime, Zeno Mercer, senior research analyst at TMX VettaFi, joins host Nate Geraci to discuss the evolution of healthcare technology.

Healthcare and technology innovation has far-reaching impacts that can truly transform and save lives. One area of ongoing focus is the growing challenge posed by heart disease.

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.